Approval · Notice of Compliance 666 · 2002
MEDROXYPROGESTERONE: Notice of Compliance 666
Issued December 6, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 666
- Date
- December 6, 2002
- Company
- Pharmel Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Progestagen
- Canadian reference product
- PROVERA (The Upjohn Company Of Canada)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MEDROXYPROGESTERONE | 02246938 | — |
| MEDROXYPROGESTERONE | 02246940 | — |
| MEDROXYPROGESTERONE | 02246941 | — |
Medicinal ingredients
- MEDROXYPROGESTERONE ACETATE 2.5 MG per TAB
- MEDROXYPROGESTERONE ACETATE 5 MG per TAB
- MEDROXYPROGESTERONE ACETATE 10 MG per TAB